Oxford Biomedica PLC — Director's Dealing 2015

Jun 16, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3208Q

Oxford Biomedica PLC

16 June 2015

Oxford BioMedica plc Director's Share Purchase

Oxford, UK - 16 June 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 16 June 2015 one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

				Interest after purchase
Director / PDMR	Title	Price per share (p)	Number of Ordinary Shares acquired	Number of Ordinary Shares	% of total issued share capital
Tim Watts	Chief Financial Officer	8.55p	116,931	5,918,934	0.23%

The issued share capital of the Group is 2,568,590,171 1p ordinary shares.

- Ends -

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: +44 (0)1865 783 000
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: +44 (0)20 3709 5700

Notes for editors

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBXGDLGGBBGUL